Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2023

Open Access 01-12-2023 | Achondroplasia | Research

Higher rates of non-skeletal complications and greater healthcare needs in achondroplasia compared to the general UK population: a matched cohort study using the CPRD database

Authors: Jeanne M. Pimenta, Melita Irving, Moira Cheung, Louise Mazzeo, Sarah Landis, Swati Mukherjee

Published in: Orphanet Journal of Rare Diseases | Issue 1/2023

Login to get access

Abstract

Background

The natural history of skeletal complications in achondroplasia (ACH) is well-described. However, it remains unclear how the rates of non-skeletal complications, surgical procedures, healthcare needs and mortality differ between individuals with ACH and the general population. This study aimed to contextualise the extent of these outcomes by comparing event rates across the lifespan, between those with ACH and matched controls in a United Kingdom (UK) population.

Methods

This retrospective, matched cohort study used data from national UK databases: the Clinical Practice Research Database (CPRD) GOLD from primary care, the secondary care Hospital Episode Statistics (HES) databases and the Office of National Statistics mortality records. ACH cases were identified using disorder-specific Read Codes or International Classification of Diseases 10th Revision codes. For each ACH case, up to four age- and sex-matched controls (defined as those without evidence of skeletal/growth disorders) were included. Event rates per 100 person-years were calculated for a pre-defined set of complications (informed by reviews of existing ACH literature and discussion with clinical authors), healthcare visits and mortality. Rate ratios (RRs) with 95% confidence intervals (CIs) were used to compare case and control cohorts.

Results

541 ACH cases and 2052 controls were identified for the CPRD cohort; of these, 275 cases and 1064 matched controls had linkage to HES data. Approximately twice as many non-skeletal complications were reported among individuals with ACH versus controls (RR [95% CI] 1.80 [1.59–2.03]). Among ACH cases, a U-shaped distribution of complications was observed across age groups, whereby the highest complication rates occurred at < 11 and > 60 years of age. Individuals with ACH had greater needs for medication, GP referrals to specialist care, medical imaging, surgical procedures and healthcare visits versus controls, as well as a mortality rate of almost twice as high.

Conclusions

Patients with ACH experience high rates of a range of both skeletal and non-skeletal complications across their lifespan. To manage these complications, individuals with ACH have significantly increased healthcare needs compared to the general population. These results underscore the need for more coordinated and multidisciplinary management of people with ACH to improve health outcomes across the lifespan.
Appendix
Available only for authorised users
Literature
1.
go back to reference Legeai-Mallet L, Savarirayan R. Novel therapeutic approaches for the treatment of achondroplasia. Bone. 2020;141:115579.CrossRefPubMed Legeai-Mallet L, Savarirayan R. Novel therapeutic approaches for the treatment of achondroplasia. Bone. 2020;141:115579.CrossRefPubMed
2.
go back to reference Foreman PK, van Kessel F, van Hoorn R, van den Bosch J, Shediac R, Landis S. Birth prevalence of achondroplasia: a systematic literature review and meta-analysis. Am J Med Genet A. 2020;182(10):2297–316.CrossRefPubMedPubMedCentral Foreman PK, van Kessel F, van Hoorn R, van den Bosch J, Shediac R, Landis S. Birth prevalence of achondroplasia: a systematic literature review and meta-analysis. Am J Med Genet A. 2020;182(10):2297–316.CrossRefPubMedPubMedCentral
5.
go back to reference Hoover-Fong JE, Alade AY, Hashmi SS, Hecht JT, Legare JM, Little ME, et al. Achondroplasia Natural History Study (CLARITY): a multicenter retrospective cohort study of achondroplasia in the United States. Genet Med. 2021;1–8. Hoover-Fong JE, Alade AY, Hashmi SS, Hecht JT, Legare JM, Little ME, et al. Achondroplasia Natural History Study (CLARITY): a multicenter retrospective cohort study of achondroplasia in the United States. Genet Med. 2021;1–8.
7.
go back to reference Pfeiffer KM, Brod M, Smith A, Gianettoni J, Viuff D, Ota S, et al. Assessing physical symptoms, daily functioning, and well-being in children with achondroplasia. Am J Med Genet A. 2021;185(1):33–45.CrossRefPubMed Pfeiffer KM, Brod M, Smith A, Gianettoni J, Viuff D, Ota S, et al. Assessing physical symptoms, daily functioning, and well-being in children with achondroplasia. Am J Med Genet A. 2021;185(1):33–45.CrossRefPubMed
8.
go back to reference Hecht JT, Bodensteiner JB, Butler IJ. Neurologic manifestations of achondroplasia. Handb Clin Neurol. 2014;119:551–63.CrossRefPubMed Hecht JT, Bodensteiner JB, Butler IJ. Neurologic manifestations of achondroplasia. Handb Clin Neurol. 2014;119:551–63.CrossRefPubMed
9.
go back to reference Aryanpur J, Hurko O, Francomano C, Wang H, Carson B. Craniocervical decompression for cervicomedullary compression in pediatric patients with achondroplasia. J Neurosurg. 1990;73(3):375–82.CrossRefPubMed Aryanpur J, Hurko O, Francomano C, Wang H, Carson B. Craniocervical decompression for cervicomedullary compression in pediatric patients with achondroplasia. J Neurosurg. 1990;73(3):375–82.CrossRefPubMed
10.
go back to reference Hunter AG, Bankier A, Rogers JG, Sillence D, Scott CI. Medical complications of achondroplasia: a multicentre patient review. J Med Genet. 1998;35(9):705–12.CrossRefPubMedPubMedCentral Hunter AG, Bankier A, Rogers JG, Sillence D, Scott CI. Medical complications of achondroplasia: a multicentre patient review. J Med Genet. 1998;35(9):705–12.CrossRefPubMedPubMedCentral
11.
go back to reference Lee ST, Song HR, Mahajan R, Makwana V, Suh SW, Lee SH. Development of genu varum in achondroplasia: relation to fibular overgrowth. J Bone Jt Surg Br Vol. 2007;89(1):57–61.CrossRef Lee ST, Song HR, Mahajan R, Makwana V, Suh SW, Lee SH. Development of genu varum in achondroplasia: relation to fibular overgrowth. J Bone Jt Surg Br Vol. 2007;89(1):57–61.CrossRef
12.
go back to reference Gollust SE, Thompson RE, Gooding HC, Biesecker BB. Living with achondroplasia in an average-sized world: an assessment of quality of life. Am J Med Genet A. 2003;120(4):447–58.CrossRef Gollust SE, Thompson RE, Gooding HC, Biesecker BB. Living with achondroplasia in an average-sized world: an assessment of quality of life. Am J Med Genet A. 2003;120(4):447–58.CrossRef
13.
go back to reference Jennings SE, Ditro CP, Bober MB, Mackenzie WG, Rogers KJ, Conway L, et al. Prevalence of mental health conditions and pain in adults with skeletal dysplasia. Qual Life Res. 2019;28(6):1457–64.CrossRefPubMed Jennings SE, Ditro CP, Bober MB, Mackenzie WG, Rogers KJ, Conway L, et al. Prevalence of mental health conditions and pain in adults with skeletal dysplasia. Qual Life Res. 2019;28(6):1457–64.CrossRefPubMed
14.
go back to reference Hoover-Fong J, Cheung MS, Fano V, Hagenas L, Hecht JT, Ireland P, et al. Lifetime impact of achondroplasia: current evidence and perspectives on the natural history. Bone. 2021;146:115872.CrossRefPubMed Hoover-Fong J, Cheung MS, Fano V, Hagenas L, Hecht JT, Ireland P, et al. Lifetime impact of achondroplasia: current evidence and perspectives on the natural history. Bone. 2021;146:115872.CrossRefPubMed
16.
go back to reference Wynn J, King TM, Gambello MJ, Waller DK, Hecht JT. Mortality in achondroplasia study: a 42-year follow-up. Am J Med Genet Part A. 2007;143(21):2502–11.CrossRef Wynn J, King TM, Gambello MJ, Waller DK, Hecht JT. Mortality in achondroplasia study: a 42-year follow-up. Am J Med Genet Part A. 2007;143(21):2502–11.CrossRef
17.
go back to reference Hashmi SS, Gamble C, Hoover-Fong J, Alade AY, Pauli RM, Modaff P, et al. Multicenter study of mortality in achondroplasia. Am J Med Genet A. 2018;176(11):2359–64.CrossRefPubMed Hashmi SS, Gamble C, Hoover-Fong J, Alade AY, Pauli RM, Modaff P, et al. Multicenter study of mortality in achondroplasia. Am J Med Genet A. 2018;176(11):2359–64.CrossRefPubMed
19.
20.
go back to reference Okenfuss E, Moghaddam B, Avins AL. Natural history of achondroplasia: a retrospective review of longitudinal clinical data. Am J Med Genet A. 2020;182(11):2540–51.CrossRefPubMed Okenfuss E, Moghaddam B, Avins AL. Natural history of achondroplasia: a retrospective review of longitudinal clinical data. Am J Med Genet A. 2020;182(11):2540–51.CrossRefPubMed
21.
go back to reference Fredwall SO, Maanum G, Johansen H, Snekkevik H, Savarirayan R, Lidal IB. Current knowledge of medical complications in adults with achondroplasia: a scoping review. Clin Genet. 2020;97(1):179–97.CrossRefPubMed Fredwall SO, Maanum G, Johansen H, Snekkevik H, Savarirayan R, Lidal IB. Current knowledge of medical complications in adults with achondroplasia: a scoping review. Clin Genet. 2020;97(1):179–97.CrossRefPubMed
22.
go back to reference Altman DG. Practical statistics for medical research: CRC press; 1990. Altman DG. Practical statistics for medical research: CRC press; 1990.
23.
go back to reference Yazaki N, Hosoi Y, Kawabata K, Miyake A, Minami M, Satoh M, et al. Differential expression patterns of mRNAs for members of the fibroblast growth factor receptor family, FGFR-1-FGFR-4, in rat brain. J Neurosci Res. 1994;37(4):445–52.CrossRefPubMed Yazaki N, Hosoi Y, Kawabata K, Miyake A, Minami M, Satoh M, et al. Differential expression patterns of mRNAs for members of the fibroblast growth factor receptor family, FGFR-1-FGFR-4, in rat brain. J Neurosci Res. 1994;37(4):445–52.CrossRefPubMed
24.
go back to reference Kunova Bosakova M, Nita A, Gregor T, Varecha M, Gudernova I, Fafilek B, et al. Fibroblast growth factor receptor influences primary cilium length through an interaction with intestinal cell kinase. Proc Natl Acad Sci USA. 2019;116(10):4316–25.CrossRefPubMedPubMedCentral Kunova Bosakova M, Nita A, Gregor T, Varecha M, Gudernova I, Fafilek B, et al. Fibroblast growth factor receptor influences primary cilium length through an interaction with intestinal cell kinase. Proc Natl Acad Sci USA. 2019;116(10):4316–25.CrossRefPubMedPubMedCentral
25.
go back to reference Duperret EK, Oh SJ, McNeal A, Prouty SM, Ridky TW. Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors. Cell Cycle. 2014;13(10):1551–9.CrossRefPubMedPubMedCentral Duperret EK, Oh SJ, McNeal A, Prouty SM, Ridky TW. Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors. Cell Cycle. 2014;13(10):1551–9.CrossRefPubMedPubMedCentral
26.
go back to reference Savarirayan R, Ireland P, Irving M, Thompson D, Alves I, Baratela WAR, et al. International consensus statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol. 2022;18(3):173–89.CrossRefPubMed Savarirayan R, Ireland P, Irving M, Thompson D, Alves I, Baratela WAR, et al. International consensus statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol. 2022;18(3):173–89.CrossRefPubMed
27.
go back to reference Maghnie M, Semler O, Guillen-Navarro E, Selicorni A, Heath KE, Haeusler G, et al. Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study. Orphanet J Rare Dis. 2023;18(1):56.CrossRefPubMedPubMedCentral Maghnie M, Semler O, Guillen-Navarro E, Selicorni A, Heath KE, Haeusler G, et al. Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study. Orphanet J Rare Dis. 2023;18(1):56.CrossRefPubMedPubMedCentral
29.
go back to reference Legare JM, Pauli RM, Hecht JT, Bober MB, Smid CJ, Modaff P, et al. CLARITY: Co-occurrences in achondroplasia—craniosynostosis, seizures, and decreased risk of diabetes mellitus. Am J Med Genet A. 2021;185(4):1168–74.CrossRefPubMed Legare JM, Pauli RM, Hecht JT, Bober MB, Smid CJ, Modaff P, et al. CLARITY: Co-occurrences in achondroplasia—craniosynostosis, seizures, and decreased risk of diabetes mellitus. Am J Med Genet A. 2021;185(4):1168–74.CrossRefPubMed
30.
go back to reference Fredwall SO, Linge J, Leinhard OD, Kjønigsen L, Eggesbø HB, Weedon-Fekjær H, et al. Cardiovascular risk factors and body composition in adults with achondroplasia. Genet Med. 2021;23(4):732–9.CrossRefPubMed Fredwall SO, Linge J, Leinhard OD, Kjønigsen L, Eggesbø HB, Weedon-Fekjær H, et al. Cardiovascular risk factors and body composition in adults with achondroplasia. Genet Med. 2021;23(4):732–9.CrossRefPubMed
Metadata
Title
Higher rates of non-skeletal complications and greater healthcare needs in achondroplasia compared to the general UK population: a matched cohort study using the CPRD database
Authors
Jeanne M. Pimenta
Melita Irving
Moira Cheung
Louise Mazzeo
Sarah Landis
Swati Mukherjee
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Achondroplasia
Published in
Orphanet Journal of Rare Diseases / Issue 1/2023
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-023-02811-5

Other articles of this Issue 1/2023

Orphanet Journal of Rare Diseases 1/2023 Go to the issue